This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Jun 2;391(10136):2187-2189.

doi: 10.1016/S0140-6736(18)31217-0. Epub 2018 Jun 1.

Psoriatic arthritis: novel targets add to a therapeutic renaissance

Peter Nash¹

Affiliations

PMID: 29893210
DOI: 10.1016/S0140-6736(18)31217-0

Comment

Psoriatic arthritis: novel targets add to a therapeutic renaissance

Peter Nash. Lancet. 2018.

. 2018 Jun 2;391(10136):2187-2189.

doi: 10.1016/S0140-6736(18)31217-0. Epub 2018 Jun 1.

Author

Peter Nash¹

Affiliation

¹ University of Queensland, Brisbane, QLD 4006, Australia. Electronic address: drpnash@tpg.com.au.

PMID: 29893210
DOI: 10.1016/S0140-6736(18)31217-0

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group. Deodhar A, et al. Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1. Lancet. 2018. PMID: 29893222 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information